BioPharmSignal logoBioPharmSignal

Biotech News

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences (GLSI)Greenwich LifeSciencesClinical readout

GLSI (GLSI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is glsi.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

GLSIGreenwich LifeSciences2026-07-20 10:00 EST

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GLSIGreenwich LifeSciences2026-08-10 10:00 EST

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

GSKGSK plc2026-09-13 19:30 EST

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

ERASErasca2026-09-10 12:00 EST

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

BMEABiomea Fusion2026-08-24 11:00 EST

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

View all latest news

Greenwich LifeSciences

Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.

Recent company news

GLSIGreenwich LifeSciences2026-08-10 10:00 EST

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

GLSIGreenwich LifeSciences2026-07-22 10:00 EST

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

GLSIGreenwich LifeSciences2026-07-20 10:00 EST

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-16 11:30 EST

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-09 10:00 EST

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Stock data

Close
18.39 USD
Market cap
356.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States